Physicochemical characterization of Remsima®

Remsima® (infliximab) was recently approved as the world's first biosimilar monoclonal antibody (mAb) in both the European Union and Korea. To achieve this, extensive physicochemical characterization of Remsima® in relation to Remicade® was conducted in order to demonstrate the highly similar p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Soon Kwan, Lee, Kyoung Hoon, Jeon, Jae Won, Lee, Joon Won, Kwon, Byoung Oh, Kim, Yeon Jung, Bae, Jin Soo, Kim, Dong-Il, Lee, Soo Young, Chang, Shin Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622713/
https://www.ncbi.nlm.nih.gov/pubmed/25517302
http://dx.doi.org/10.4161/mabs.32221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622713/
https://www.ncbi.nlm.nih.gov/pubmed/25517302
http://dx.doi.org/10.4161/mabs.32221

Ejemplares similares